Provider Engagement Clearinghouse

• Cardiologist’s Perceptions of Access to New Therapies 2016 survey (ACC)Revealed that implementing new therapies is a problem, requiring more professional time due to administrative barriers; The top two barriers to trying new therapies are a) cost and b) prior authorization documentation; Cardiologists feel very favorably about prescribing new medications. And, cardiologists would be much more likely to prescribe appropriate new therapies if they did not experience delays/denials.
• Provider survey on challenges in prescribing PCSK9 (NLA)A healthcare provider’s competency in dyslipidemia management requires a thorough understanding of existing and emerging evidence-based therapies that they can utilize in clinical practice. Watch these short videos and learn about the NLA‘s provider survey as well as some of the preliminary results found about the challenges to access PCSK9 therapy.
• FOCUS analysis (FH Foundation)Shows that regardless of medical need, prescriptions for PCSK9 inhibitors are being rejected at high rates.

• Support of legislation such as California’s Senate Bill 866 (NLA)The California Department of Managed Health Care and the Department of Insurance developed a mandatory Prescription Drug Prior Authorization Request Form.
• The Prior Authorization Coalition17 members including ACC, AMA, American Pharmacists Association, and Medical Group Management Association. Medical Group Management Association, state medical associations/societies (OH, MN, WA, NC) is calling for an industry-wide reassessment of prior authorization, following a set of 21 principles.
• PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payersSeth J. Baum, Peter P. Toth, James A. Underberg, Paul Jellinger, Joyce Ross, Katherine Wilemon
• Access to Innovative Medicines Tip SheetDeveloped by the Preventive Cardiovascular Nurses Association, this is a critical reference includes tips and resources for how to navigate administrative systems, maximize efficiency of the prior authorization process, and improve nurse job satisfaction and adherence/patient outcomes. Particularly focused on PCSK9, NOAC and new heart failure therapies.

• PCSK9i Patient Access Prior Authorization Out-of-Of Pocket CostArticle published in JAMA Cardiology evaluating patient access to PCSK9i among those prescribed therapy using pharmacy transaction data.
• Town Hall initiatives article on Eliminating Access Barriers to PCSK9 Inhibitors (ASPC)

• Project ImPACT Diabetes (APhA Foundation)

TOOLS & RESOURCES

• What is FH?…And What Do I Do About It?” (legal size)A Shared Decision Making tool designed for patients and providers to use in role modeling conversation on discussing FH and treatment options, created in collaboration with the FH Foundation and American Pharmacists Association Foundation (legal size document)
• What is FH?…And What Do I Do About It?” (letter size)
• What are Statin-Related Side Effects?…And What Do I Do About Them?” (legal size) A Shared Decision Making tool designed for patients and providers to use in role modeling conversation on discussing statin-related side effects and treatment options, created in collaboration with the National Lipid Association and American Pharmacists Association Foundation (legal size document)
• What are Statin-Related Side Effects?…And What Do I Do About Them?” (letter size)
• What is Atheroscelrotic Cardiovascular Disease (ASCVD)?…And What Do I Do About It?” (Legal Size) A Shared Decision Making tool designed for patients and providers to use in role modeling conversation on discussing ASCVD and treatment options, created in collaboration with the American Pharmacists Association Foundation (legal size document)
• What is Atheroscelrotic Cardiovascular Disease (ASCVD)?…And What Do I Do About It?” (Letter Size)

• Enhancing the Value of PCSK9 Monoclonal Antibodies by Identifying Patients Most Likely to Benefit Robinson JG, Jayanna MB, Brown AS, et. al.
• Determining When to Add Nonstatin Therapy A Quantitative Approach Robinson JG, Huijgen R, Ray K, et. al.
• Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab Pooled Data From Randomized Trials Robinson JG, Rosenson RS,  Farnier M, et. al.